结直肠癌免疫评分系统:现状与展望
本文综述了结直肠癌中多种免疫评分系统,重点介绍了基于CD3+和CD8+ T细胞密度数字图像分析的Immunoscore®。肿瘤内CD3+、CD8+和CD45RO+ T细胞浸润与良好临床结局高度相关,免疫评分有助于判断局限性和转移性结直肠癌的预后并可能指导治疗。文章还讨论了各评分系统的性能、局限性和未来改善患者管理的潜力。
要点
- 肿瘤内CD3+、CD8+和CD45RO+ T细胞浸润与结直肠癌良好预后强相关。
- Immunoscore®基于肿瘤中心与浸润边缘的CD3+和CD8+淋巴细胞密度免疫组化数字分析。
- 免疫评分有望辅助判断局限性和转移性结直肠癌的预后及治疗决策。
核心结论
- 结直肠癌免疫评分系统(尤其Immunoscore®)可能有助于定义预后并指导局限性和转移性结直肠癌的治疗。
研究设计与样本
- 本文为综述,聚焦结直肠癌中已开发的不同免疫评分系统及其性能、局限性和未来潜力。
主要发现
- 肿瘤内CD3+ T细胞、CD8+细胞毒性T细胞和CD45RO+记忆T细胞浸润是与结直肠癌良好临床结局最一致且最强的免疫参数。
关键数值与推荐
- Immunoscore®基于免疫组化结合数字图像分析系统测定肿瘤中心及浸润边缘的CD3+和CD8+淋巴细胞密度。
临床怎么用
- 临床可依据肿瘤中心及浸润边缘CD3+和CD8+淋巴细胞密度评估免疫评分,辅助判断结直肠癌预后并可能指导治疗决策。
局限性
- 不同免疫评分系统存在各自的局限性,原文指出需关注其性能与不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is growing evidence that the immune system may prevent the occurrence, growth and metastatic diffusion of colorectal cancer (CRC). The role played by the adaptive immune response at the tumour site is critical in the balance between tumour invasion and defence against cancer. Recent data have shown that the evaluation of this immune response may help to define the prognosis and possibly the treatment of localised CRC as well as metastatic CRC. Tumour infiltrates with T cells (CD3+), cytotoxic T cells (CD8+) and memory T cells (CD45RO+) are the immune parameters most consistently and strongly associated with good clinical outcome in CRC. Several scoring systems have been developed, including the Immunoscore®, based on the immunohistochemical determination with a digital image analysis system of the density of CD3+ and CD8+ lymphocytes in the centre and the invasive margin of the tumour. This review will focus on the different immunoscoring systems developed in CRC, their performance, their limitations and their potential for improving patients' care in the future.
引用
- Malka D, Lièvre A, André T, et al. Immune scores in colorectal cancer: Where are we? Eur J Cancer. 2020. PMID: 33075623. doi:10.1016/j.ejca.2020.08.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。